Characterization of the effect of a novel γ-secretase modulator on Aβ: A clinically translatable model

Current Pharmaceutical Design

Volumn 20, Issue 15, 2014, Pages 2484-2490

  Portelius, Erik ^a   Appelkvist, Paulina ^b   Strömberg, Kia ^b,c,d   Höglund, Kina ^c  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c SCIENCE FOR LIFE LABORATORY   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Alzheimer's disease; Biomarkers; CSF; Plasma; Pre clinical model; Translation; Treatment; amyloid (A ); secretase modulator

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AZ 4126; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; GAMMA SECRETASE MODULATOR; UNCLASSIFIED DRUG; AMYLOID PRECURSOR PROTEIN; SECRETASE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CEREBROSPINAL FLUID; CYTOTOXICITY; DOSE TIME EFFECT RELATION; GUINEA PIG; HUMAN; HUMAN CELL; MALE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; THERAPY EFFECT; ANIMAL; DISEASE MODEL; METABOLISM;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; DISEASE MODELS, ANIMAL; GUINEA PIGS; HUMANS; MALE;

EID: 84903725622     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990499     Document Type: Article

References (22)

1. Citron M. Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov 2010; 9:3 87-398.
2. Portelius E, Mattsson N, Andreasson U, et al. Novel abeta isoforms in Alzheimer's disease-their role in diagnosis and treatment. Curr Pharm Des 2011; 17: 2594-602.
3. Best JD, Smith DW, Reilly MA, et al. The novel gamma secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl) cyclohexyl]-1,1,1-trifl uoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notchrelated pathology in the Tg2576 mouse. J Pharmacol ExpTher 2007; 320: 552-8.
4. Cirrito JR, May PC, O'Dell MA, et al. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci 2003; 23: 8844-53.
5. Dovey HF, John V, Anderson JP, et al. Functional gammasecretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem 2001; 76: 173-81.
6. Imbimbo BP, Giardina GA. gamma-secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes. Curr Top Med Chem 2011; 11: 1555-70.
7. Fleisher AS, Raman R, Siemers ER, et al. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol 2008; 65: 1031-8.
8. Bateman RJ, Siemers ER, Mawuenyega KG, et al. A gammasecretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol 2009; 66: 48-54.
9. Sambamurti K, Greig NH, Utsuki T, et al. Targets for AD treatment: conflicting messages from gamma-secretase inhibitors. J Neurochem 2011; 117: 359-74.
10. Siemers ER, Dean RA, Friedrich S, et al. Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. Clin Neuropharmacol 2007; 30: 317-25.
11. Peretto I, La Porta E. Gamma-secretase modulation and its promise for Alzheimer's disease: a medicinal chemistry perspective. Curr Top Med Chem 2008; 8: 38-46.
12. Portelius E, Zhang B, Gustavsson MK, et al. Effects of gammasecretase inhibition on the amyloid beta isoform pattern in a mouse model of Alzheimer's disease. Neurodegener Dis 2009; 6: 258-62.
13. Portelius E, Dean RA, Gustavsson MK, et al. A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease. Alzheimers Res Ther 2010; 2: 7.
14. Coric V, van Dyck CH, Salloway S, et al. Safety and Tolerability of the gamma-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease. Arch Neurol 2012; 69: 1-12.
15. Wanngren J, Ottervald J, Parpal S, et al. Second generation gamma-secretase modulators exhibit different modulation of Notch beta and Abeta production. J Biol Chem 2012; 287: 32640-50.
16. Jeppsson F, Eketjall S, Janson J, et al. Discovery of AZD3839, a potent and selective BACE1 clinical candidate for the treatment of Alzheimers Disease. J Biol Chem 2012; 287: 41245-57.
17. Portelius E, Tran AJ, Andreasson U, et al. Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. J Proteome Res 2007; 6: 4433-9.
18. Vanderstichele H, Van Kerschaver E, Hesse C, et al. Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid 2000; 7: 245-58.
19. Portelius E, Van Broeck B, Andreasson U, et al. Acute effect on the Abeta isoform pattern in CSF in response to gamma-secretase modulator and inhibitor treatment in dogs. J Alzheimers Dis 2010; 21: 1005-12.
20. Cook JJ, Wildsmith KR, Gilberto DB, et al. Acute gammasecretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-beta production to alternative APP fragments without amyloid-beta rebound. J Neurosci 2010; 30: 6743-50.
21. Du P, Wood KM, Rosner MH, et al. Dominance of amyloid precursor protein sequence over host cell secretases in determining beta-amyloid profiles studies of interspecies variation and drug action by internally standardized immunoprecipitation/mass spectrometry. J Pharmacol Exp Ther 2007; 320: 1144-52.
22. Borgegard T, Jureus A, Olsson F, et al. First and second generation gamma-secretase modulators (GSMs) modulate amyloid-beta (Abeta) peptide production through different mechanisms. J Biol Chem 2012; 287: 11810-9.